Trials / Completed
CompletedNCT03375047
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 Administered by Nebulization to Adult Subjects With Cystic Fibrosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1/2, first-in-human study evaluated the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with cystic fibrosis (CF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRT5005 | Nebulization of MRT5005 |
| DRUG | Normal saline | Normal Saline for Inhalation |
Timeline
- Start date
- 2018-05-10
- Primary completion
- 2022-03-15
- Completion
- 2022-03-15
- First posted
- 2017-12-15
- Last updated
- 2026-02-09
- Results posted
- 2026-02-09
Locations
16 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03375047. Inclusion in this directory is not an endorsement.